Showing posts with label acetazolamide. Show all posts
Showing posts with label acetazolamide. Show all posts

Monday, August 4, 2008

18 - posner-schlossman syndrome

Glaucomatocyclitic crisis is a condition with self-limited recurrent episodes of markedly elevated intraocular pressure (IOP) with mild idiopathic anterior chamber inflammation. It is most often classified as secondary inflammatory glaucoma. In 1948, Posner and Schlossman first recognized glaucomatocyclitic crisis and described the features of this syndrome. For this reason, the entity is often termed Posner-Schlossman syndrome (PSS). They identified the following features:

  • Recurrent episodes of mild cyclitis
  • Uniocular involvement
  • Duration of attack varying from a few hours to several weeks
  • Signs of a slight decrease in vision, elevated IOP with open angles, corneal edema with a few keratic precipitates, heterochromia with anisocoria, and a large pupil in the affected eye
  • Normal visual fields
  • Normal optic disc
  • Normal IOP, outflow facility, and all provocative tests between episodes

Since this original description, other cases attributed to glaucomatocyclitic crisis have been found to deviate from these criteria. For instance, some patients with glaucomatocyclitic crisis have abnormal aqueous humor dynamics and may have an underlying primary open-angle glaucoma (POAG). Additional features that are now recognized are as follows:

  • Almost exclusively, this condition affects individuals aged 20-50 years.
  • Both eyes may be involved at different times but very rarely contemporaneously.
  • The rise of IOP is out of proportion to the severity of the uveitis, and this rise in IOP precedes the identifiable inflammatory reaction, often by several days.

Episodic changes in the trabecular meshwork lead to impairment of outflow facility and result in an elevation of IOP. These changes are accompanied by mild intraocular inflammation. In the acute phase of PSS, optic nerve head parameters and retinal flow rates were altered; however, all returned to normal without any permanent damage after resolution of the elevated IOP. Electroretinogram studies in the acute phase demonstrate a selective reduction in the S-cone b-wave.

Causes :

  • The etiology of glaucomatocyclitic crisis has remained elusive. Several factors have been postulated as contributors to the development of glaucomatocyclitic crisis, to include the following:

·

    • Abnormal vascular process
    • Autonomic defect
    • Allergic condition
    • Variation of developmental glaucoma
    • Cytomegalovirus (CMV)
    • Herpes simplex virus
  • Description of a final common pathway usually includes a reference to changes in the trabecular meshwork leading to a reduction of outflow facility. However, some authors describe an increase in aqueous production.
  • Transfer coefficients of fluorescein in aqueous in the anterior chamber, by flow and by diffusion, are elevated during attacks of glaucomatocyclitic crisis. Between attacks, both coefficients return to normal.
  • Elevations in IOP are postulated to be secondary to inflammation of the trabecular meshwork, which may be mediated by prostaglandins.
  • Prostaglandins, especially prostaglandin E, have been found in higher concentration in the aqueous humor of patients during acute attacks. These levels return to normal between episodes.

·

    • In a study using rabbit eyes, prostaglandin E was shown to contribute to a breakdown of the blood-aqueous barrier. This increase in the transfer coefficient of fluorescein is consistent with a similar response in animal eyes to prostaglandin E.
    • The vascular effects of prostaglandins may contribute to the tortuosity seen in iris vessels and the leakage demonstrated with fluorescein angiography of the iris.
    • To confuse matters, in another animal study, elevated prostaglandins increased outflow facility, which would contribute to a lower IOP and, thus, not be consistent with the reduced outflow facility seen in patients with glaucomatocyclitic crisis during an acute episode.
    • Another theory purports an increased aqueous production resulting from elevated levels of aqueous prostaglandins.
    • In summary, the exact mechanism by which prostaglandins regulate IOP has not been described, but a direct correlation between elevated levels of prostaglandins in the aqueous humor and the level of IOP has been found during acute attacks of glaucomatocyclitic crisis.
  • Evidence exists that glaucomatocyclitic crisis may be associated with POAG. Patients with a 10-year or longer history of PSS are 3 times more likely to develop visual field changes and optic disc changes. These patients may have a higher than normal incidence of corticosteroid responsiveness, leading to an elevated IOP. This must be kept in mind during the treatment of this disorder with corticosteroids.
  • Associations with immunogenetic factors also exist; in one study, the presence of human leukocyte antigen Bw54 (HLA-Bw54) was found in 41% of patients.
  • Associations with certain allergic conditions and gastrointestinal diseases, most notably peptic ulcer disease, have been described.

Physical examination of the eye :

  • On examination, the eye is quiet with either no injection or a mild ciliary flush.
  • The pupil often is dilated slightly or sluggishly reactive; the anterior chamber is deep and has an open angle.
  • This condition should be differentiated from closed-angle glaucoma with the help of gonioscopy.
  • IOP usually is elevated in the range of 40-60 mm Hg.
  • IOP is related to the duration of uveitis but not to the degree of uveitis.
  • Eyes with active inflammatory disease often have wide swings in IOP, leading to glaucomatous damage.
  • The elevated IOP can last for several hours to a few weeks; therefore, it can be missed on initial examination.
  • If the elevated IOP is of significant duration and elevation, corneal epithelial edema develops.
  • Signs of anterior inflammation are characteristically minimal with faint flare, rare cells, and only a few keratic precipitates that are stellate, flat, nonpigmented, and concentrated over the inferior half of the endothelium.
  • Fine keratic precipitates appear after 2-3 days of elevated IOP and resolve rapidly.
  • The inflammation never leads to the development of posterior synechiae or peripheral anterior synechiae.
  • Fresh precipitates may appear with each episode of increased IOP.
  • Heterochromia, described originally, is no longer considered a characteristic of this syndrome.
  • Typical of inflammatory conditions, early segmental iris ischemia and associated late iris-vessel congestion have been observed. These vessels leak on iris fluorescein angiography.

Treatment :

Complete medical care for patients presenting with glaucomatocyclitic crisis includes a reasonably thorough history of present illness, a review of drug allergies and sensitivities, a targeted past medical history and review of systems, a complete eye examination, a careful explanation of the disorder in accordance with the patient's level of understanding, and a commitment to long-term follow-up care of the patient.

  • Medical therapy should be individualized to meet the patient's needs. Currently, the favored initial treatment is a combined regimen of a topical nonsteroidal anti-inflammatory drug (NSAID) and an antiglaucoma drug.
  • Treatment recommendations include the following:

·

    • Topical steroids - Prednisolone acetate 1% 1 gtt qid, followed by taper
    • Topical antiglaucoma drops - Timolol 0.25-0.5% 1 gtt bid or equivalent, or dorzolamide 2% 1 gtt bid/tid or equivalent (Beta-blockers should be avoided in patients with asthma.)
    • Systemic carbonic anhydrase inhibitors - Acetazolamide 250 mg PO qid
    • Topical NSAIDs - Diclofenac 0.1% 1 gtt tid/qid or equivalent
    • Oral NSAIDs - Indomethacin 75-150 mg/d PO
  • Miotics and mydriatic agents seldom are used because they may have further deleterious effects on the blood-aqueous barrier, and long-acting periocular steroids are frowned upon because of lingering IOP effects.
  • NSAIDs reduce the inflammatory component by inhibiting the production of prostaglandins, and antiglaucoma medications reduce the influx of new aqueous; both these effects rapidly control the IOP. This combination also avoids potential IOP elevations caused by steroids in steroid-responsive patients.
  • Well-informed and educated patients often can sense an impending attack based on ocular symptomatology, and they can institute appropriate self-therapy using an aqueous suppressant and a topical NSAID to blunt IOP elevations associated with treatment delays.
  • Carefully observe patients periodically for recurrences of attacks and for development of POAG.
  • In the absence of underlying chronic glaucoma, antiglaucoma agents do not prevent recurrences of glaucomatocyclitic crisis; therefore, they are not necessary between episodes.

An occasional patient may require a filtering procedure, which is not effective in preventing recurrences of the episodes of iritis but may be useful in the management of high IOP seen with these episodes. For example, a patient with excessively high pressures threatening vascular perfusion would be a candidate for a filtering procedure. No benefit is gained from laser trabeculoplasty.

Sunday, March 2, 2008

14 - acute angle closure glaucoma - drug therapy


The goal in treatment of AACG is to reduce IOP. Medical management is the first step. A prompt reduction in IOP using topical and systemic medication decreases the duration of elevated IOP and the potential for visual field loss. IOP reduction is accomplished via suppression of aqueous humor production, eliminating pupillary block, and reversing inflammation. As with any medical intervention, intimate knowledge of the drugs, their indications, contraindications, and potential side effects can aid the physician in providing the best treatment and a favorable outcome.

Drug Category: Carbonic anhydrase inhibitors

These are first-line agents that should be used immediately during the initial intervention. They reduce bicarbonate production in the ciliary epithelium and therefore decrease aqueous formation.

Drug NameAcetazolamide (Diamox)
DescriptionReduces rate of aqueous humor formation by direct inhibition of enzyme carbonic anhydrase (CA) on secretory ciliary epithelium, causing, in turn, a reduction in IOP. More than 90% of CA must be inhibited before IOP reduction can occur. May reduce IOP by 40-60%. Effects are seen in about an hour, they peak in 4 h, and trough in about 12 h. Derived chemically from sulfa drugs. If one form is not well tolerated, another form may be better or lower dose of the drug may better tolerated. IV administration of this medication may be used for rapid relief of increased IOP. A beneficial effect occurs when used with miotics or mydriatics.
Adult Dose500 mg IV stat, followed by 500 mg PO
Pediatric Dose5-10 mg/kg/dose IV/IM, then 0-15 mg/kg/d PO divided q6-8h
ContraindicationsDocumented hypersensitivity; hepatic disease; severe renal disease; adrenocortical insufficiency; severe pulmonary obstruction
InteractionsCan decrease therapeutic levels of lithium and alter excretion of drugs (amphetamines, quinidine, phenobarbital, salicylates) by alkalinizing urine
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsPatients with impaired hepatic function may go into coma; may cause substantial increase in blood glucose level in some diabetic patients

Drug NameMethazolamide (Neptazane)
DescriptionReduces aqueous humor formation by inhibiting enzyme carbonic anhydrase, which results in decreased IOP.
Adult Dose50-100 mg PO bid/tid
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; renal impairment
InteractionsMay increase toxicity of salicylate, digoxin; coadministration with other diuretics may induce hypokalemia; decreases effects of lithium and alter excretion of other drugs by alkalinizing urine
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in respiratory acidosis and diabetes mellitus; impairs mental alertness and/or physical coordination; hematuria, glycosuria, polyuria, hepatic insufficiency, bone marrow suppression, thrombocytopenia/purpura, agranulocytosis, urticaria, pruritus, and rash may occur

Drug Category: Beta-adrenergic blockers

These agents may lower IOP via their suppression of aqueous humor production and probably not through any affects on the pupil.

Drug NameTimolol (Timoptic, Timoptic XE)
DescriptionReduces elevated and normal IOP by reducing aqueous humor production or possibly the outflow.
Adult Dose1 gtt of 0.25% or 0.5% solution in affected eye(s) bid; if IOP is maintained at satisfactory levels, reduce dosage to 1 gtt qd in affected eye(s)
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; bronchial asthma; sinus bradycardia; second- and third-degree AV block; severe chronic obstructive pulmonary disease; overt cardiac failure; cardiogenic shock
InteractionsMay cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsProduct may have sulfites, which may cause allergic-type reactions in susceptible patients; may exacerbate or precipitate heart block, asthma, chronic obstructive pulmonary disease, mental changes (especially in the elderly persons)

Drug NameCarteolol (Ocupress)
DescriptionNonselective beta-adrenergic receptor. Blocks beta1- and beta2-receptors and has mild intrinsic sympathomimetic activity (ISA), with possibly fewer cardiac and lipid profile adverse effects. Precise mechanism by which carteolol decreases IOP is thought to be through reduction of aqueous formation.
Adult Dose1 gtt in affected eye(s) bid
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; congestive heart failure; asthma; cardiac conduction defects; breastfeeding
InteractionsMay cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsProduct may have sulfites, which may cause allergic-type reactions in certain susceptible persons

Drug NameLevobetaxolol (Betaxon)
DescriptionSelectively blocks beta1-adrenergic receptors with little or no effect on beta2-receptors. Reduces IOP by reducing production of aqueous humor.
Adult Dose1 gtt in affected eye(s) bid
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second- and third-degree AV block; overt cardiac failure; cardiogenic shock
InteractionsMay have additive systemic effects if patient is already on systemic beta-blockers
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsBeta-blockade may potentiate muscle weakness consistent with myasthenic symptoms; product may have sulfites, which may cause hypersensitivity reactions in susceptible persons

Drug NameLevobunolol (AKBeta, Betagan)
DescriptionNonselective beta-adrenergic blocking agent that lowers IOP by reducing aqueous humor production and may increase outflow of aqueous humor.
Dosages of more than 1 gtt of 0.5% levobunolol twice daily have not been shown to be more effective. If IOP not at satisfactory level on this regimen, concomitant therapy can be instituted. However, do not administer 2 or more topical ophthalmic beta-adrenergic blocking agents simultaneously.
Adult Dose0.5% solution: 1-2 gtt in affected eye(s) qd
0.25% solution: 1-2 gtt in affected eye(s) bid
Severe or uncontrolled glaucoma: 0.5% solution bid; closely monitor patient
>1 gtt (0.5% levobunolol) bid not shown to be more effective; if IOP not at satisfactory level on this regimen, concomitant therapy can be instituted; do not administer 2 or more topical ophthalmic beta-adrenergic blocking agents simultaneously
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second- and third-degree AV block; overt cardiac failure; cardiogenic shock
InteractionsMay cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsBeta-blockade may potentiate muscle weakness that is consistent with certain myasthenic symptoms (eg, diplopia, ptosis, generalized weakness); product may have sulfites, which may cause allergic-type reactions in certain susceptible persons

Drug Category: Alpha-adrenergic agonists

These agents are used as adjunct agents to further decrease IOP secondary to their affect on aqueous humor production.

Drug NameApraclonidine (Iopidine)
DescriptionPotent alpha-adrenergic agent selective for alpha2-receptors with minimal cross-reactivity to alpha1-receptors. Suppresses aqueous production. Reduces elevated, as well as normal, IOP whether or not accompanied by glaucoma. Apraclonidine is relatively selective alpha-adrenergic agonist that does not have significant local anesthetic activity. Has minimal cardiovascular effects.
Adult Dose1 gtt of 0.5% or 1% in affected eye(s) tid
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; patients on MAO inhibitors or have taken them in the past 14 d
InteractionsMonitor pulse and BP frequently when giving cardiovascular drugs; not for use concurrently with MAO inhibitors
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsMay exacerbate or precipitate ocular irritation, topical sensitivity, vasovagal attack and optic nerve ischemia in patients with advanced glaucomatous optic neuropathy

Drug NameBrimonidine (Alphagan, Alphagan-P)
DescriptionSelective alpha2 receptor that may reduce aqueous humor formation, may decrease inflow, or may increase uveoscleral outflow.
Adult Dose1 gtt in affected eye tid
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; patients receiving MAO inhibitor therapy
InteractionsCoadministration with topical beta-blockers may further decrease IOP; tricyclic antidepressants may decrease effects of brimonidine; CNS depressants such as barbiturates, opiates, and sedatives may potentiate effects of brimonidine
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsMay exacerbate or precipitate ocular irritation, topical sensitivity, vasovagal attack and optic nerve ischemia in patients with advanced glaucomatous optic neuropathy

Drug Category: Corticosteroids

These agents reduce ocular inflammation thereby providing symptomatic relief and augmenting the affects of other medications.

Drug NamePrednisolone (AK-Pred, Econopred)
DescriptionUsed in treatment of acute inflammations following eye surgery or other insults to the eye.
In cases of bacterial infections, concomitant use of anti-infective agents is mandatory. If signs and symptoms do not improve after 2 d, reevaluate the patient. Dosing may be reduced, but advise patients not to discontinue therapy prematurely.
Adult DoseSolution: 1-2 gtt of solution into conjunctival sac up to q1h during day and q2h at night prn
When a favorable response observed, reduce dosage to 1 gtt q4h; further reduction in dosage to 1 gtt tid/qid may suffice to control symptoms
Susp: Shake well before using; 1-2 gtt into conjunctival sac bid/qid; during initial 24-48 h, dosing frequency may be increased prn
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; viral, fungal, or tubercular skin lesions
InteractionsDecreases effects of salicylates and toxoids (for immunizations); phenytoin, carbamazepine, barbiturates, and rifampin decrease effects of corticosteroids
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in hyperthyroidism, osteoporosis, cirrhosis, nonspecific ulcerative colitis, peptic ulcer, diabetes, and myasthenia gravis

Drug Category: Ophthalmic agents, miotic

These agents pull the peripheral iris tissue away from the trabecular meshwork helping to eliminate obstructed aqueous humor flow. They are ineffective during the initial period due to the ischemic paralysis of the iris. Miotics should be used after the immediate management and initial reduction of IOP.

Drug NamePilocarpine (Pilagan, Pilocar, Pilostat)
DescriptionPatients may be maintained on pilocarpine as long as IOP is controlled and no deterioration in visual fields is present. May be used alone or in combination with other miotics, beta-adrenergic blocking agents, epinephrine, carbonic anhydrase inhibitors, or hyperosmotic agents to decrease IOP.
Frequency of instillation and concentration are determined by patient's response. Individuals with heavily pigmented irides may require higher strengths.
Adult DoseSolution: 1-2 gtt tid/qid
Gel: Apply 0.5-inch ribbon in the lower conjunctival sac of affected eye(s) hs
If another glaucoma medication being used hs, use gtt at least 5 min before gel
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; acute inflammatory disease of anterior chamber
InteractionsMay be ineffective when used concomitantly with nonsteroidal anti-inflammatory agents
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in acute cardiac failure, peptic ulcer, hyperthyroidism, GI spasm, bronchial asthma, Parkinson disease, recent MI, urinary tract obstruction, and hypertension or hypotension

Drug Category: Hyperosmotics

Hyperosmotic agents increase serum osmolarity and cause a fluid shift from the eye into the vascular space. The subsequent osmotic diuresis reduces IOP.

Drug NameGlycerin (Osmoglyn)
DescriptionUsed in glaucoma to interrupt acute attacks. Reduces IOP through its diuretic effects. Adds to tonicity of blood until metabolized and eliminated by kidneys. Maximal reduction of IOP occurs 1 h after glycerin administration. The effect lasts approximately 5 h.
Adult Dose1-2 g/kg PO and repeat q5h prn; alternatively, 1 mL/kg PO as a 50% solution in juice
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; frank or impending acute pulmonary edema, anuria, severe dehydration, and severe cardiac decompensation
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsAdminister orally, never parenterally; for oral use only; avoid in acute urinary retention in preoperative period; continued use may result in weight gain; caution in hypervolemia, diabetes, severely dehydrated individuals, confused mental states, congestive heart disease, and cardiac, renal, or hepatic disease

Drug NameIsosorbide (Ismotic)
DescriptionIn the eyes, creates an osmotic gradient between plasma and ocular fluids. Induces diuresis by elevating osmolarity of glomerular filtrate, thereby hindering tubular reabsorption of water. May be used to interrupt an acute attack of glaucoma. Use when less risk of nausea and vomiting, compared with other oral hyperosmotic agents, is needed.
Adult Dose1.5 g/kg PO initially, followed by 1-3 g/kg PO bid/qid prn
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; anuria, severe dehydration, frank or impending acute pulmonary edema, and severe cardiac decompensation
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsUse repetitive doses with caution, particularly in patients with diseases associated with salt retention

Drug NameMannitol (Osmitrol)
DescriptionReduces elevated IOP when pressure cannot be lowered by other means.
Initially assess for adequate renal function in adults by administering a test dose of 200 mg/kg IV over 3-5 min. Should produce a urine flow of at least 30-50 mL/h of urine over 2-3 h.
In children, assess for adequate renal function by administering a test dose of 200 mg/kg IV over 3-5 min. Should produce a urine flow of at least 1 mL/h over 1-3 h.
Adult Dose1.5-2 g/kg IV as 20% solution (7.5-10 mL/kg) or as 15% solution (10-13 mL/kg) over a period as short as 30 min
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; anuria, severe pulmonary congestion, progressive renal damage, severe dehydration, active intracranial bleeding, and progressive heart failure
InteractionsMay decrease serum lithium levels
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCarefully evaluate cardiovascular status before rapid administration of mannitol since a sudden increase in extracellular fluid may lead to fulminating CHF; avoid pseudoagglutination, when blood given simultaneously, add at least 20 mEq of sodium chloride to each liter of mannitol solution; do not give electrolyte-free mannitol solutions with blood

Saturday, January 12, 2008

1 - glaucoma mcqs

Question 1
Essential feature of glaucoma is:
Optic neuropathy-----------
Raised intraocular pressure
Reduced vision
Painful eye

Question 2
Which of these is not a feature of ocular hypertension?
Elevated intraocular pressure
Closed angle-------------
Normal visual fields
Normal optic discs

Question 3
Risk factors for glaucoma include:
Cardiovascular diseases
Family history of glaucoma
Hypothyroidism
All of the above------------

Question 4
Which of these is not a likely cause of painful red eye in a patient?
Open angle glaucoma------------
Closed angle glaucoma
Conjunctivitis
Herpes simplex

Question 5
Drugs that facilitate aqueous humor outflow include:
Timolol
Pilocarpine
Epinephrine
B and C only-----------

Question 6
Which one of the following agents lowers intraocular pressure by reducing aqueous production?
Latanoprost
Dorzolamide--------------( carbonic anhydrase inhibitor )
Epinephrine
Pilocarpine

Question 7
Which class of drug is the first line of therapy for open angle glaucoma when no contraindication exists?
ß blockers----------------
a agonist
Carbonic anhydrase inhibitors
Prostaglandins

Question 8
Side effects of oral carbonic anhydrase inhibitors include:
Tingling sensation in the extremities
Nausea and vomiting
Fatigue
All of the above---------------

Question 9
Dorzolamide is a:
Oral carbonic anhydrase inhibitor
Topical carbonic anhydrase inhibitor-----------
Prostaglandin
None of the above

Question 10
Which one of the following statements regarding pilocarpine is true?
It is a sympathomimetic drug
It is the mainstay of glaucoma treatment
It can be employed in the treatment of both open angle and closed angle glaucoma--------------
It reduces production of aqueous humor

Question 11
Uveo-scleral outflow of aqueous humor is increased by:
Prostaglandins------------
ß blockers
Alpha agonist
Carbonic anhydrase inhibitors

Question 12
Which of the following are not suitable adjuncts?
Timolol and latanoprost
Pilocarpine and betaxolol
Dorzolamide and timolol
Brimonidine and betaxolol-------------?????

Question 13
In treatment of glaucoma, to achieve better effect blockers can be combined well with:
Miotics
Topical carbonic anhydrase inhibitors
Prostaglandins
Any of the above-----------

Question 14
A 75 year old lady with a long standing history of asthma treated with steroids presents to the clinic because of decreased vision. She is found to have posterior capsular opacities as well as an intraocular pressure of 28 mmHg. Which of the following medication should be prescribed?
Timolol
Pilocarpine
Latanoprost----------------
None of the above

Question 15
Neuroprotection is well established with:
Timolol
Brimonidine-----------
Latanoprost
None of the above

Question 16
The only US FDA approved drug for control of post-operative intraocular pressure spikes is:
Brimonidine 0.2%
Apraclonidine 1%-----------------
Latanoprost 0.005%
None of the above

Question 17
Which of these is not true with regard to laser trabeculoplasty?
It is done as an outpatient procedure
A new opening is created in the white of the eye to facilitate drainage of aqueous humor------------
Its effects may wear off over time
Is generally done after trying treatment with medications

Google
 

Subscribe Now: Feed

You are visitor number

Visitors currently online